• Explore /
  • Poster
  • / Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

Abstract Poster

Authors

null

Renee Maria Saliby

Dana-Farber Cancer Institute, Boston, MA

Renee Maria Saliby , Wanling Xie , J Connor Wells , Eddy Saad , Marc Eid , Chris Labaki , Karl Semaan , Evan Ferrier , Audreylie Lemelin , Cristina Suárez , Jose Manuel Ruiz-Morales , Thomas Powles , Lori Wood , Hedyeh Ebrahimi , Guillermo de Velasco , Kosuke null Takemura , Neeraj Agarwal , David A. Braun , Daniel Yick Chin Heng , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 400)

DOI

10.1200/JCO.2024.42.4_suppl.400

Abstract #

400

Poster Bd #

G3

Abstract Disclosures

Similar Posters

First Author: Dimitrios Makrakis

First Author: Stuthi Perimbeti

First Author: Viktor Grünwald

First Author: Geraldine Pignot